{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:04:41Z","timestamp":1784581481338,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"A.C. has received grants from Gilead and Bristol-Myers Squibb (BMS), travel grants and speaker's honoraria from Abbvie, BMS, Merck Sharp & Dohme (MSD), Gilead, Janssen-Cilag, and Viiv."},{"name":"G.D.P. has received grants, travel grants and consultancy fees from Abbvie, Boehringer-Inghelheim, BMS, MSD, Gilead, Janssen-Cilag, and Viiv."},{"name":"S.B. has received grants, travel grants and consultancy fees from Abbvie, Boehringer-Inghelheim, BMS, MSD, Gilead, Janssen-Cilag, and Viiv."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41397-019-0109-x","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:35:14Z","timestamp":1571254514000},"page":"202-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients"],"prefix":"10.1038","volume":"20","author":[{"given":"Jessica","family":"Cusato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-8815","authenticated-orcid":false,"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Marinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Avataneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u02b9Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"109_CR1","doi-asserted-by":"crossref","unstructured":"Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, et al. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. Lancet HIV. 2017;4:e270\u20136.","DOI":"10.1016\/S2352-3018(17)30029-2"},{"key":"109_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1586\/14787210.1.3.415","volume":"1","author":"JE Gallant","year":"2003","unstructured":"Gallant JE, Pham PA. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection. Expert Rev Anti Infect Ther. 2003;1:415\u201322.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"109_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2217\/pgs-2016-0003","volume":"17","author":"A Calcagno","year":"2016","unstructured":"Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? Pharmacogenomics. 2016;17:531\u20134.","journal-title":"Pharmacogenomics"},{"key":"109_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/FPC.0000000000000110","volume":"25","author":"A Dahlin","year":"2015","unstructured":"Dahlin A, Wittwer M, de la Cruz M, Woo JM, Bam R, Scharen-Guivel V, et al. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics. 2015;25:82\u201392.","journal-title":"Pharmacogenet Genomics"},{"key":"109_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1179\/1945577115Y.0000000004","volume":"16","author":"LG Hemkens","year":"2015","unstructured":"Hemkens LG, Ewald H, Santini-Oliveira M, Buhler JE, Vuichard D, Schandelmaier S, et al. Comparative effectiveness of tenofovir in treatment-naive HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015;16:178\u201389.","journal-title":"HIV Clin Trials"},{"key":"109_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2217\/pgs.09.115","volume":"10","author":"S Rodriguez-Novoa","year":"2009","unstructured":"Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009;10:1675\u201385.","journal-title":"Pharmacogenomics"},{"key":"109_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1086\/378068","volume":"37","author":"JE Gallant","year":"2003","unstructured":"Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:944\u201350.","journal-title":"Clin Infect Dis"},{"key":"109_CR8","first-page":"37","volume":"14","author":"P Maggi","year":"2012","unstructured":"Maggi P, Bartolozzi D, Bonfanti P, Calza L, Cherubini C, Di Biagio A, et al. Renal complications in HIV disease: between present and future. AIDS Rev. 2012;14:37\u201353.","journal-title":"AIDS Rev"},{"key":"109_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/QAD.0000000000000901","volume":"30","author":"JL Casado","year":"2016","unstructured":"Casado JL, Banon S, Santiuste C, Serna J, Guzman P, Tenorio M, et al. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir. AIDS. 2016;30:231\u20139.","journal-title":"AIDS"},{"key":"109_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496\u2013505.","journal-title":"Clin Infect Dis"},{"key":"109_CR11","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283112b8e","volume":"22","author":"JE Gallant","year":"2008","unstructured":"Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155\u201363.","journal-title":"AIDS"},{"key":"109_CR12","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1097\/QAD.0b013e32834bba87","volume":"25","author":"SM Vrouenraets","year":"2011","unstructured":"Vrouenraets SM, Fux CA, Wit FW, Garcia EF, Furrer H, Brinkman K, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 2011;25:2149\u201355.","journal-title":"AIDS"},{"key":"109_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/QAD.0000000000000995","volume":"30","author":"A Calcagno","year":"2015","unstructured":"Calcagno A, Cusato J, Marinaro L, Simiele M, Lucchiari M, Alcantarini C, et al. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. AIDS. 2015;30:915\u201320.","journal-title":"AIDS"},{"key":"109_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","volume":"26","author":"R Scherzer","year":"2012","unstructured":"Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867\u201375.","journal-title":"AIDS"},{"key":"109_CR15","doi-asserted-by":"publisher","first-page":"e1001809","DOI":"10.1371\/journal.pmed.1001809","volume":"12","author":"A Mocroft","year":"2015","unstructured":"Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12:e1001809.","journal-title":"PLoS Med"},{"key":"109_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/QAI.0b013e31827ce4ee","volume":"62","author":"I Poizot-Martin","year":"2012","unstructured":"Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2012;62:375\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"109_CR17","unstructured":"Scarpino M, Santoro MM, Pellicano\u2019 G. HIV infection and kidney disease: literature review. Infect Dis Trop Med. 2015;1:1\u20138."},{"key":"109_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2497-3","volume":"17","author":"SE Salvaggio","year":"2017","unstructured":"Salvaggio SE, Giacomelli A, Falvella FS, Oreni ML, Meraviglia P, Atzori C, et al. Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients. BMC Infect Dis. 2017;17:396.","journal-title":"BMC Infect Dis"},{"key":"109_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/508546","volume":"194","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481\u201391.","journal-title":"J Infect Dis"},{"key":"109_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/infdis\/jir215","volume":"204","author":"SP Pushpakom","year":"2011","unstructured":"Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204:145\u201353.","journal-title":"J Infect Dis"},{"key":"109_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/QAI.0b013e31815e7478","volume":"47","author":"JJ Kiser","year":"2008","unstructured":"Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:298\u2013303.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"109_CR22","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/cid\/cis772","volume":"55","author":"T Nishijima","year":"2012","unstructured":"Nishijima T, Komatsu H, Higasa K, Takano M, Tsuchiya K, Hayashida T, et al. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. Clin Infect Dis. 2012;55:1558\u201367.","journal-title":"Clin Infect Dis"},{"key":"109_CR23","doi-asserted-by":"publisher","first-page":"e0147724","DOI":"10.1371\/journal.pone.0147724","volume":"11","author":"S Likanonsakul","year":"2016","unstructured":"Likanonsakul S, Suntisuklappon B, Nitiyanontakij R, Prasithsirikul W, Nakayama EE, Shioda T, et al. A single-nucleotide polymorphism in ABCC4 is associated with tenofovir-related beta2-microglobulinuria in thai patients with HIV-1 infection. PLoS ONE. 2016;11:e0147724.","journal-title":"PLoS One"},{"key":"109_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11904-016-0315-y","volume":"13","author":"AC Achhra","year":"2016","unstructured":"Achhra AC, Nugent M, Mocroft A, Ryom L, Wyatt CM. Chronic kidney disease and antiretroviral therapy in HIV-positive individuals: recent developments. Curr HIV\/AIDS Rep. 2016;13:149\u201357.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"109_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.clpt.6100269","volume":"83","author":"JJ Kiser","year":"2008","unstructured":"Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir\/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharm Ther. 2008;83:265\u201372.","journal-title":"Clin Pharm Ther"},{"key":"109_CR26","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1128\/AAC.04930-14","volume":"59","author":"K Rungtivasuwan","year":"2015","unstructured":"Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger DM, Ruxrungtham K, et al. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59:3240\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"109_CR27","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1086\/598507","volume":"48","author":"S Rodriguez-Novoa","year":"2009","unstructured":"Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108\u201316.","journal-title":"Clin Infect Dis"},{"key":"109_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QAD.0000000000000112","volume":"28","author":"Z Neumanova","year":"2014","unstructured":"Neumanova Z, Cerveny L, Ceckova M, Staud F. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014;28:9\u201317.","journal-title":"AIDS"},{"key":"109_CR29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/labinvest.2011.48","volume":"91","author":"JJ Kohler","year":"2011","unstructured":"Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 2011;91:852\u20138.","journal-title":"Lab Invest"},{"key":"109_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.apsb.2016.07.003","volume":"6","author":"H Lu","year":"2016","unstructured":"Lu H. Crosstalk of HNF4alpha with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B. 2016;6:393\u2013408.","journal-title":"Acta Pharm Sin B"},{"key":"109_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/tpj.2015.71","volume":"16","author":"A Calcagno","year":"2015","unstructured":"Calcagno A, Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, et al. Clinical pharmacology of tenofovir clearance: a pharmacokinetic\/pharmacogenetic study on plasma and urines. Pharmacogenomics J. 2015;16:514\u20138.","journal-title":"Pharmacogenomics J"},{"key":"109_CR32","doi-asserted-by":"crossref","unstructured":"Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32:981\u201391.","DOI":"10.1089\/aid.2016.0008"},{"key":"109_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.diagmicrobio.2018.07.001","volume":"94","author":"J Cusato","year":"2019","unstructured":"Cusato J, Calcagno A, De Nicolo A, Mogyorosi K, D\u2019Avolio A, Di Perri G, et al. Tenofovir alafenamide and tenofovir disoproxil fumarate are not transported by concentrative nucleoside transporter 2. Diagn Microbiol Infect Dis. 2019;94:202\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"109_CR34","first-page":"5120831","volume":"2016","author":"E Lerma-Chippirraz","year":"2016","unstructured":"Lerma-Chippirraz E, Guerri-Fernandez R, Villar Garcia J, Gonzalez Mena A, Guelar Grinberg A, Montero MM, et al. Validation protocol of vitamin D supplementation in patients with HIV-infection. AIDS Res Treat. 2016;2016:5120831.","journal-title":"AIDS Res Treat"},{"key":"109_CR35","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1128\/AAC.01096-13","volume":"57","author":"PL Havens","year":"2013","unstructured":"Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 2013;57:5619\u201328.","journal-title":"Antimicrob Agents Chemother"},{"key":"109_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","volume":"10","author":"CL Woodward","year":"2009","unstructured":"Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482\u20137.","journal-title":"HIV Med"},{"key":"109_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/QAI.0b013e3181caebaa","volume":"54","author":"MM Rosenvinge","year":"2010","unstructured":"Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54:496\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"109_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/aid.2011.0052","volume":"28","author":"M Masia","year":"2012","unstructured":"Masia M, Padilla S, Robledano C, Lopez N, Ramos JM, Gutierrez F. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2012;28:242\u20136.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"109_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1089\/aid.2009.0308","volume":"26","author":"KE Childs","year":"2010","unstructured":"Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, et al. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26:855\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"109_CR40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/cid\/cir968","volume":"54","author":"PL Havens","year":"2012","unstructured":"Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis. 2012;54:1013\u201325.","journal-title":"Clin Infect Dis"},{"key":"109_CR41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1310\/hct1306-350","volume":"13","author":"A Bech","year":"2012","unstructured":"Bech A, Van Bentum P, Telting D, Gisolf J, Richter C, De Boer H. Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy. HIV Clin Trials. 2012;13:350\u20136.","journal-title":"HIV Clin Trials"},{"key":"109_CR42","doi-asserted-by":"publisher","first-page":"e103055","DOI":"10.1371\/journal.pone.0103055","volume":"9","author":"D Canale","year":"2014","unstructured":"Canale D, de Braganca AC, Goncalves JG, Shimizu MH, Sanches TR, Andrade L, et al. Vitamin D deficiency aggravates nephrotoxicity, hypertension and dyslipidemia caused by tenofovir: role of oxidative stress and renin-angiotensin system. PLoS ONE. 2014;9:e103055.","journal-title":"PLoS ONE"},{"key":"109_CR43","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1210\/jc.2008-1212","volume":"94","author":"O Tarcin","year":"2009","unstructured":"Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94:4023\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"109_CR44","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.nut.2011.10.014","volume":"28","author":"MD Borges-Santos","year":"2012","unstructured":"Borges-Santos MD, Moreto F, Pereira PC, Ming-Yu Y, Burini RC. Plasma glutathione of HIV(+) patients responded positively and differently to dietary supplementation with cysteine or glutamine. Nutrition. 2012;28:753\u20136.","journal-title":"Nutrition"},{"key":"109_CR45","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1089\/aid.2008.0058","volume":"24","author":"CJ Van Den Bout-Van Den Beukel","year":"2008","unstructured":"Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375\u201382.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"109_CR46","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1055\/s-0028-1104337","volume":"101","author":"H Kuhlmann","year":"1976","unstructured":"Kuhlmann H. [Therapy of diabetic glomerulosclerosis (Kimmelstiel-Wilson syndrome)]. Dtsch Med Wochenschr. 1976;101:1769\u201372.","journal-title":"Dtsch Med Wochenschr"},{"key":"109_CR47","first-page":"1517","volume":"27","author":"T Michigami","year":"2017","unstructured":"Michigami T. Update on recent progress in vitamin D research. Vitamin D Metabolism and Its Regulation. Clin Calcium. 2017;27:1517\u201323.","journal-title":"Clin Calcium"},{"key":"109_CR48","unstructured":"Begley R, Martin H, Lawson EB, Wei X, Vimal M, Marbury TC, et al. (2014). Pharmacokinetics and safety of tenofovir alafenamide in subjects with mild or moderate hepatic impairment In: Proceedings of the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC."},{"key":"109_CR49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","volume":"4","author":"A Hill","year":"2018","unstructured":"Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4:72\u20139.","journal-title":"J Virus Erad"},{"key":"109_CR50","first-page":"915","volume":"62","author":"RP Walensky","year":"2015","unstructured":"Walensky RP, Horn TH, Paltiel AD. The Epi-TAF for tenofovir disoproxil fumarate? Clin Infect Dis. 2015;62:915\u20138.","journal-title":"Clin Infect Dis"},{"key":"109_CR51","unstructured":"Lazio GR (2017). Aggiornamento del Decreto \u201cRazionalizzazione dell\u2019uso dei farmaci per la terapia antiretroviraIe HIV\u201d: Rome. \nhttp:\/\/www.regione.lazio.it\/binary\/rl_sanita\/tbl_normativa\/SAN_DCA_U00244_28_06_2017.pdf\n\n."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0109-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0109-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0109-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:03Z","timestamp":1684616403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0109-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["109"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0109-x","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"18 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AC has received grants from Gilead and Bristol-Myers Squibb (BMS), travel grants and speaker\u2019s honoraria from Abbvie, BMS, Merck Sharp & Dohme (MSD), Gilead, Janssen-Cilag, and Viiv. GDP and SB have received grants, travel grants and consultancy fees from Abbvie, Boehringer-Inghelheim, BMS, MSD, Gilead, Janssen-Cilag, and Viiv. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}